Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS

Byungha Chung, J. Y. Lee, S. H. Lee, S. J. Yoo, S. W. Lee, C. Y. Oh

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl] -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.

Original languageEnglish
Pages (from-to)122-128
Number of pages7
JournalInternational Journal of Impotence Research
Volume21
Issue number2
DOIs
Publication statusPublished - 2009 Mar 9

Fingerprint

udenafil
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Erectile Dysfunction
Safety
Heart Rate
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{81e6f6964daa44ca9ab0262f62df5123,
title = "Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS",
abstract = "We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl] -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.",
author = "Byungha Chung and Lee, {J. Y.} and Lee, {S. H.} and Yoo, {S. J.} and Lee, {S. W.} and Oh, {C. Y.}",
year = "2009",
month = "3",
day = "9",
doi = "10.1038/ijir.2009.2",
language = "English",
volume = "21",
pages = "122--128",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "2",

}

Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS. / Chung, Byungha; Lee, J. Y.; Lee, S. H.; Yoo, S. J.; Lee, S. W.; Oh, C. Y.

In: International Journal of Impotence Research, Vol. 21, No. 2, 09.03.2009, p. 122-128.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS

AU - Chung, Byungha

AU - Lee, J. Y.

AU - Lee, S. H.

AU - Yoo, S. J.

AU - Lee, S. W.

AU - Oh, C. Y.

PY - 2009/3/9

Y1 - 2009/3/9

N2 - We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl] -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.

AB - We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl] -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.

UR - http://www.scopus.com/inward/record.url?scp=62449215028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449215028&partnerID=8YFLogxK

U2 - 10.1038/ijir.2009.2

DO - 10.1038/ijir.2009.2

M3 - Article

VL - 21

SP - 122

EP - 128

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 2

ER -